More stories

  • in

    Trump-Allied Prosecutor Sends Letters to Medical Journals Alleging Bias

    An interim U.S. attorney is demanding information about the selection of research articles and the role of N.I.H. Experts worry this will have a chilling effect on publications.A federal prosecutor has sent letters to at least three medical journals accusing them of political bias and asking a series of probing questions suggesting that the journals mislead readers, suppress opposing viewpoints and are inappropriately swayed by their funders.The letters were signed by Edward Martin Jr., a Republican activist serving as interim U.S. attorney in Washington, D.C. He has been criticized for using his office to target opponents of President Trump.Some scientists and doctors said they viewed the letters as a threat from the Trump administration that could have a chilling effect on what journals publish. The health secretary, Robert F. Kennedy Jr., has said he wants to prosecute medical journals, accusing them of lying to the public and colluding with pharmaceutical companies.One of the letters was sent to the journal Chest, published by the American College of Chest Physicians. The New York Times obtained a copy of the letter.The Times confirmed that at least two other publishers had received nearly identically worded letters, but those publishers would not speak publicly because they feared retribution from the Trump administration.In the letter to Chest, dated Monday, Mr. Martin wrote, “It has been brought to my attention that more and more journals and publications like CHEST Journal are conceding that they are partisans in various scientific debates.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    A Harvard Scientist’s Tuberculosis Research Is Threatened by Trump’s Cuts

    Researchers who have lost funds warned of long-term repercussions, but several said their school should still refuse to comply with the federal government.Dr. Sarah Fortune, an immunologist who spends a lot of time in her laboratory at Harvard, never expected to be caught in a battle with the White House.But early Tuesday morning, she received an official notice to “stop work” on her lab’s federally funded research on tuberculosis, an infectious disease that kills more than a million people a year worldwide.Just hours earlier, the Trump administration had vowed to freeze $2.2 billion in research funding at Harvard. If fully executed, it will be the deepest cut yet in a White House campaign against elite universities that began shortly after President Trump took office in January. Other universities, including Princeton, Cornell and Columbia, have also seen deep cuts to research funding.Dr. Fortune’s contract, a $60 million National Institutes of Health agreement involving Harvard and other universities across the country, appeared to be one of the first projects affected. Stop-work notices also began arriving this week at an obscure Harvard office called “sponsored programs” that coordinates federal research funding.One Harvard professor, David R. Walt, received a notice that his research toward a diagnostic tool for Lou Gehrig’s disease, or A.L.S., must stop immediately. Two other orders will affect research on space travel and radiation sickness, just weeks after the scientist, Dr. Donald E. Ingber, who engineers fake organs that are useful in studies of human illnesses, was approached by the government to expand his work.David R. Walt at his lab at Harvard Medical School, where he does research searching for a diagnostic tool for Lou Gehrig’s disease, or A.L.S.Cody O’Loughlin for The New York TimesWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    Experts Doubt Kennedy’s Timetable for Finding the Cause of Autism

    The nation’s health secretary announced that he planned to invite scientists to provide answers by September, but specialists consider that target date unrealistic.Robert F. Kennedy Jr., the nation’s health secretary, pledged on Thursday to seek out experts globally to discover the reasons for the increasing rates of autism in the United States.“We’ve launched a massive testing and research effort that’s going to involve hundreds of scientists from around the world,” Mr. Kennedy announced at a cabinet meeting held by President Trump. “By September, we will know what has caused the autism epidemic and we’ll be able to eliminate those exposures.”“There will be no bigger news conference than that,” Mr. Trump replied.But scientists who have worked for decades to find a cause greeted Mr. Kennedy’s predicted timeline with skepticism.They said that a single answer would be hard to identify in a field of possible contributors including pesticides, air pollution and maternal diabetes.Dr. Philip Landrigan, a pediatrician and expert on environmental toxins, pointed to the current mass layoffs and cutbacks for research at Mr. Kennedy’s Department of Health and Human Services as one reason for doubting such quick progress.“Given that a great deal of research on autism and other pediatric diseases in hospitals and medical schools is currently coming to a halt because of federal funding cuts from H.H.S.,” he said, “it is very difficult for me to imagine what profound scientific breakthrough could be achieved between now and September.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    Trump’s Nominee for N.I.H. Chief Faces Questions From Senators

    Dr. Jay Bhattacharya, a Stanford University health economist who came to prominence crusading against lockdowns during the coronavirus pandemic, faced questioning from the Senate health committee on Wednesday morning as President Trump’s nominee to direct the National Institutes of Health.The agency, the world’s largest funder of biomedical research, with a $48 billion budget and 27 separate institutes and centers, has been rocked lately by the Trump administration’s efforts to block government spending and shrink the federal work force. Hours before Wednesday’s hearing, the Department of Government Efficiency, the cost-cutting group led by Elon Musk, trumpeted the cancellation of N.I.H. grants.Dr. Bhattacharya, who has a medical degree and is a professor of medicine but has never practiced, has expressed an interest in restructuring the agency and reducing the power of “scientific bureaucrats” who he has said end up “dominating a field for a very long time.”His views on medicine and public health have at times put Dr. Bhattacharya at odds with many of the scientists whose research the N.I.H. oversees.While he has defended vaccines and has said he was dubious that they caused autism, Dr. Bhattacharya told an interviewer last year that he could not rule out a link. “I don’t know that for a fact,” he said. Extensive evidence shows no link between immunizations and autism.Dr. Bhattacharya became a go-to witness in court cases challenging Covid policies, including mask mandates. In several cases, judges said he was disregarding facts or was untrustworthy. His detractors note that while he has published studies on health policy issues — like drug prices and the link between different types of health insurance and H.I.V. deaths — he is not a scientist conducting biomedical research, the core mission of the agency.But supporters have said that Dr. Bhattacharya could bring needed reform to the N.I.H. and have defended some of his contrarian views on Covid.Dr. Bhattacharya burst into the news at the height of the pandemic in October 2020, when he co-wrote an anti-lockdown treatise, the Great Barrington Declaration, that argued for “focused protection” — a strategy that would focus on protecting the elderly and vulnerable while letting the virus spread among younger, healthier people.The nation’s medical leadership, including Dr. Francis S. Collins and Dr. Anthony S. Fauci, then director of the National Institute of Allergy and Infectious Diseases, denounced the plan. Referring to Dr. Bhattacharya and his co-authors as “fringe epidemiologists,” Dr. Collins wrote in an email that “there needs to be a quick and devastating takedown of its premises.”Dr. Collins, who later stepped down as the N.I.H. director to pursue his laboratory research, retired last week in anticipation of Dr. Bhattacharya’s arrival. More

  • in

    Three Years: Reflections on the Ukraine War

    More from our inbox:Advice for Democrats: ‘Go Home and Listen’Lab Discoveries LostBuy Back Pennies and NickelsRe-evaluating Movies Andrew Kravchenko/Associated PressTo the Editor:Re “At Home and Abroad, Mourning Lives Lost Over Three Long Years” (news article, Feb. 25):Feb. 24 marked the third anniversary of the Russian invasion of Ukraine. I am inspired by, and my heart breaks for, the brave and noble Ukrainians. I wish my president were more like President Volodymyr Zelensky.Alison FordOssining, N.Y.To the Editor:Re “Dueling U.N. Resolutions on Ukraine Highlight Fissures Between the U.S. and Europe” (news article, Feb. 25):If the United States’ joining Russia to vote against a United Nations resolution to condemn Russia’s war against Ukraine isn’t giving aid and comfort to our enemy, I don’t know what is. Shame on us all.Eileen MitchellLewes, Del.To the Editor:Republicans, historically the party for a strong U.S. foreign policy and an understanding of who our democratic allies are, now remain silent.As President Trump embraces Vladimir Putin, widely suspected of being a killer of political rivals and journalists, and calls President Volodymyr Zelensky a dictator, our Republican senators and representatives should understand that their silence is more than acquiescence.It should be construed as supporting our current path. So when things go wrong, as they inevitably do when you cut deals with bad actors, don’t you dare pretend you were not a part of this abhorrent change in direction in U.S. policy.Steve ReichShort Hills, N.J.To the Editor:Re “Ukraine Nears a Deal to Give U.S. a Share of Its Mineral Wealth” (news article, nytimes.com, Feb. 24):I want to register my objection to the United States’ “mineral rights” demand to Ukraine. Further, any treaty granting our nation such rights must be approved by Congress, which I hope will show a shred of dignity and ensure that it at least gives Ukraine protection and sovereignty in return.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State

    A proposal by the Trump administration to reduce the size of grants for institutions conducting medical research would have far-reaching effects, and not just for elite universities and the coastal states where many are located. Also at risk could be grants from the National Institutes of Health to numerous hospitals that conduct clinical research on […] More

  • in

    Deep Cuts to Medical Research Funds Could Hobble University Budgets

    The National Institutes of Health announced a new policy Friday to cap a type of funding that supports medical research at universities, a decision that most likely will leave many with a large budget gap. The policy targets $9 billion in so-called indirect funds that the N.I.H. sends along with direct funds to support research into basic science and treatments for diseases ranging from cancer to Alzheimer’s to diabetes.Currently, some universities get 50 percent or more of the amount of a grant in indirect funds, meaning a $1 million research award would come with $500,000 to maintain facilities and equipment and pay support staff. The new policy would cap those indirect funds at 15 percent.“I think it’s going to destroy research universities in the short term, and I don’t know after that,” said Dr. David A. Baltrus, a University of Arizona associate professor whose lab is developing antibiotics for crops. “They rely on the money. They budget for the money. The universities were making decisions expecting the money to be there.”Dr. Baltrus said that his research is focused on efforts such as keeping E. coli bacteria out of crops like sprouts and lettuce. He said the policy change would force his university to make cuts to support staff and overhead.The Trump administration has been sharply critical of what it derides as “woke” policies and cultures at universities, which have been bracing for a hit to their budgets. Project 2025, a set of conservative policy proposals, called for capping these related research funds, saying they were sometimes used to fund diversity, equity and inclusion initiatives. Cutting such costs would “reduce federal taxpayer subsidization of leftist agendas,” Project 2025’s authors said.An N.I.H. social media post said the change could save the federal government as much as $4 billion and sharply cut payments to Harvard, Yale and Johns Hopkins Universities, which have overhead rates above 60 percent of their grant sums.Senator Patty Murray, a Democrat of Washington, said in a statement late Friday that the move could “dismantle the biomedical research system, stifle the development of new cures for disease, and rip treatments away from patients in need.”She said the change could shut down some clinical trials at institutions in her state, such as the Fred Hutchinson Cancer Center and University of Washington.The N.I.H. spent about $35 billion in 2023 on about 50,000 competitive grants to about 300,000 researchers at 2,500 universities, medical schools and other research institutions nationwide, according to the new policy. Of that, about $26 billion directly funded research and $9 billion covered indirect costs. The policy is set to take effect Monday. More

  • in

    Don’t Cut an Agency So Vital to Our Health

    More from our inbox:Needed: More Maternity WardsRacial Inequities in the Overdose CrisisVet the Presidential CandidatesTech Tycoons in ChargeA building on the N.I.H. campus in Bethesda, Md. The agency comprises 27 institutes and has a budget of $48 billion.Hailey Sadler for The New York TimesTo the Editor:Re “Long Government’s ‘Crown Jewel,’ Health Institute Is Becoming a Target” (news article, Dec. 3):Your article describes the National Institutes of Health as a “crown jewel” of the federal government based on its track record of success in driving medical and health research and innovation. The article also captures the longstanding bipartisan support for the agency and its work.When asked in a national survey we commissioned this year, Americans of all political persuasions expressed their support for federally funded research:Eighty-eight percent of Americans agree that basic scientific research is necessary and should be supported by the federal government.Some 62 percent would be willing to pay $1 per week more in taxes to support additional medical and health research.And 89 percent say it is important that the U.S. is a global leader in research to improve health.Continuing to treat the N.I.H. as a top national priority is a strategy that will spur new treatments and cures for the health threats facing our population. It will also drive U.S. business and job growth across the life science, technology, manufacturing and service sectors that in the end will keep us globally competitive.Mary WoolleyNew YorkThe writer is the president and C.E.O. of Research!America.To the Editor:The suggestion to cut infectious disease funding displays dangerous historical amnesia. Just as the 1918-20 flu pandemic killed millions of people globally, Covid-19’s emergence in 2020 demonstrated how quickly a novel pathogen can upend society. While vaccines helped curb Covid-19’s impact, we face an equally urgent crisis: antibiotic resistance.Currently, drug-resistant bacteria infect over two million Americans annually, causing more than 20,000 deaths. Without sustained funding and research, projections show antimicrobial resistance could cause 10 million annual deaths globally by 2050.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More